Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 MilliporeSigma Invests $25M to Expand Cell Culture Media Production | Contract Pharma

What are you searching for?

Sign in
Breaking News

MilliporeSigma Invests $25M to Expand Cell Culture Media Production

Boosts capabilities with additional 98,000 sq.-ft. of manufacturing and redesigned lab space.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt Germany, has expanded its facility in Lenexa, KS, adding 98,000 square feet of lab space and production capability to manufacture cell culture media.

The company’s strategic investments to expand capacity with the new dry powder media manufacturing lines in existing production facilities in Lenexa and Nantong, China, sites will increase both local and global production to meet current demand and ensure supply for future demand surges.

“The Lenexa expansion reflects our commitment to meeting the dynamic needs of our customers worldwide and delivering on our growth plans,” said Darren Verlenden, head of process solutions, Life Science. “This expansion makes Lenexa the company’s largest dry powder cell culture media facility and Center of Excellence in North America. Investing in the region reflects our strategy to expand and diversify our supply chain to ensure we meet current and future demand for cell culture media.”

Verlenden added, “As our customers’ needs and technologies evolve, so must we. The new production line represents the company’s vision for our Lenexa site, as it was initially constructed for three manufacturing lines for dry powder cell culture media. The new production line is the culmination of multiple years of planning, and now we are able to offer greater flexibility and faster cell culture media manufacturing for our customers.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics